Electra Therapeutics, Inc.
ETRA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002088082
In the last 90 days, Electra Therapeutics, Inc. insiders filed 3 open-market purchases and 0 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Key figures
- Market capNo recent share count in SEC filings
- –
- Insider buysLast 90 days, $24.3M in total
- 3
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026
- 0
- 13F valueReported value at the end of Q2 2026
- $0
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 484.0K
- Shares sold short
- Change
- +74.6K
- +18.2% vs. previous
- Days to cover
- 1.70
- At average daily volume
Superinvestors holding ETRA, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding ETRA at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Electra Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 10, 2026 (view filing)8:14 PM ET | Nov 6-10 | 4 days | Gordon Carl LDirector, 10% Owner | PPurchase | +92.1K | $8.08 | +$744.5K | +4.4%2.19M after | 6 lotsDuplicate filing |
| Nov 10, 2026 (view filing)8:09 PM ET | Nov 6-10 | 4 days | OrbiMed Advisors LLC and 2 othersDirector, 10% Owner | PPurchase | +92.1K | $8.08 | +$744.5K | +4.4%2.19M after | 6 lots |
| Nov 5, 2026 (view filing)5:47 PM ET | Nov 3-5 | 2 days | Gordon Carl LDirector, 10% Owner | PPurchase | +472.6K | $7.63 | +$3.61M | +28.4%2.14M after | 10 lotsDuplicate filing |
| Nov 5, 2026 (view filing)5:39 PM ET | Nov 3-5 | 2 days | OrbiMed Advisors LLC and 2 othersDirector, 10% Owner | PPurchase | +472.6K | $7.63 | +$3.61M | +28.4%2.14M after | 10 lots |
| Sep 23, 2026 (view filing)5:35 PM ET | Sep 21 | 2 days | Gordon Carl LDirector, 10% Owner | PPurchase | +1.33M | $15.00 | +$20.0M | +313.8%1.76M after | 2 lotsDuplicate filing |
| Sep 23, 2026 (view filing)5:29 PM ET | Sep 21 | 2 days | OrbiMed Advisors LLC and 2 othersDirector, 10% Owner | PPurchase | +1.33M | $15.00 | +$20.0M | +313.8%1.76M after | 2 lots |
Top 10 13F holders, Q2 2026
View all: Top 10 13F holders, Q2 2026The largest institutional positions in Electra Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
No institution reported holding ETRA in 13F filings for Q2 2026.
Holders of 5% or more of ETRA
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Electra Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| OrbiMed Advisors LLC | 13D | 11.00%6.89M shares | New | Sep 25, 20261 filing | Sep 25, 2026 | SEC |
| Westlake BioPartners Fund I, L.P. | 13G | 10.10%6.35M shares | New | Oct 29, 20261 filing | Oct 29, 2026 | SEC |
| Redmile Group, LLC | 13G | 8.70%5.46M shares | New | Sep 28, 20261 filing | Sep 28, 2026 | SEC |
| LSP 7 Cooperatief U.A. | 13G | 6.00%3.80M shares | New | Sep 28, 20261 filing | Sep 28, 2026 | SEC |